SubHero Banner

Libtayo® (cemiplimab-rwlc) – Expanded indication

November 8, 2022 - Regeneron announced the FDA approval of Libtayo (cemiplimab-rwlc), in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation; or metastatic.

Download PDF